We are planning a Cochrane systematic review about the role of methylxanthines to prevent and treat intermittent hypoxia and respiratory insufficiency  in late preterm infants (gestational age > or equal 34 weeks)

As parents or healthcare professional (nurse, respiratory therapist, pediatrician, neonatologist), we invite you to participate by answering this brief question to know your thoughts and concerns about this therapy in late preterm infants.

For parents:

**Given that your baby has experienced shorts and intermittent drops of oxygen saturation while he/she was awake, sleeping, feeding or during kangaroo position, what was your biggest concern?

For healthcare providers: **Given that in your clinical practice you have used methylxanthines for late preterm infants to prevent or treat intermittent hypoxia or to treat the need of respiratory support or apneas episodes, what do you think it would be the main benefit of those babies at short term and at long term with the treatment? for example: reduce major neurodevelopmental disability, mortality, length of hospital stay, need for invasive respiratory support, other?

**Do you have any concern of using methylxanthines for late preterm infants in terms of adverse events? (please list your concerns, tachycardia, feeding intolerance, sleeplessness, hyperglycemia, hypertension, heart arrhythmias, growth failure, others)

Parents or healthcare professional (nurse, respiratory therapist, pediatrician, neonatologist) caring for late preterm infants. Time to answer two short questions. Thank you for participating, your opinion is very valuable for us to enrich the perspective, values and preferences of consumers of this therapy in this systematic review for the late preterm infants population